Inflammatory lipid mediator pathway

The inflammatory lipid mediator pathway, often referred to as the eicosanoid cascade, is a complex biochemical network responsible for the production of potent signaling molecules derived from polyunsaturated fatty acids, primarily arachidonic acid (Dennis & Norris, 2011, Nature Reviews Immunology). Key enzymes in this pathway include phospholipase A2 (PLA2), which releases arachidonic acid from cell membranes, and the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, which convert it into prostaglandins, thromboxanes, and leukotrienes (Vane & Botting, 1998, American Journal of Medicine). These mediators play fundamental roles in the initiation, maintenance, and resolution of inflammation, as well as in regulating vascular tone and pain perception (Serhan, 2014, Nature). Dysregulation of these lipid mediators is central to the pathogenesis of chronic inflammatory conditions such as rheumatoid arthritis, asthma, and atherosclerosis (Funk, 2001, Science). Therapeutic strategies widely target this pathway using nonsteroidal anti-inflammatory drugs (NSAIDs) to inhibit COX enzymes or leukotriene modifiers to manage respiratory conditions (StatPearls, 2023). Modern research also focuses on specialized pro-resolving mediators (SPMs) like resolvins and protectins, which actively promote the resolution of inflammation rather than just inhibiting its onset (Buckley et al., 2014, Immunity).

Other names

Eicosanoid signaling pathwayArachidonic acid cascadeLipid mediator signalingBioactive lipid pathway

Inhibition of cyclooxygenase (COX-1/COX-2) enzymes to prevent prostaglandin synthesis; antagonism of cysteinyl leukotriene receptors (CysLT1); inhibition of 5-lipoxygenase (5-LOX) to prevent leukotriene production; and activation of specialized pro-resolving mediator (SPM) receptors.